No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on ArriVent BioPharma, Maintains $25 Price Target
Buy Rating for ArriVent BioPharma Amid Strong Financials and Promising Clinical Trials
Buy Rating Affirmed for ArriVent BioPharma on Strong Firmonernib Prospects and Financial Stability
ArriVent BioPharma Q1 EPS $(0.70) Beats $(1.05) Estimate
ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(1.05) by 33.33 percent.
Express News | Arrivent Biopharma, Inc.: Qtrly Shr Loss $0.70
ArriVent BioPharma | 10-Q: Quarterly report
No Data